BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio.
Mission-driven to preserve human life
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment.
40 Churchway London
Post Code: NW1 1LW
Country: United Kingdom
Membership Type: Corporate 51+